In a USA study, monogenic diabetes genetic screening approach was modeled as being cost-effective at 6% yield and cost-saving at 30% yield for GCK, HNF1A, HNF4A, with an estimated combined prevalence of 2%, implicating the most clinically actionable changes to therapy113. This evidence concerns the gene HNF1A and diabetes mellitus.